CN1273150C - Medicine for treating depression and its preparing method - Google Patents
Medicine for treating depression and its preparing method Download PDFInfo
- Publication number
- CN1273150C CN1273150C CN 03117484 CN03117484A CN1273150C CN 1273150 C CN1273150 C CN 1273150C CN 03117484 CN03117484 CN 03117484 CN 03117484 A CN03117484 A CN 03117484A CN 1273150 C CN1273150 C CN 1273150C
- Authority
- CN
- China
- Prior art keywords
- medicine
- depression
- radix
- present
- caulis acanthopanacis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 86
- 229940079593 drug Drugs 0.000 title claims description 16
- 238000000034 method Methods 0.000 title claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 208000020401 Depressive disease Diseases 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- -1 each reflux Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 244000141009 Hypericum perforatum Species 0.000 abstract 1
- 235000017309 Hypericum perforatum Nutrition 0.000 abstract 1
- 230000002898 effect on depression Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 241000581650 Ivesia Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000001430 anti-depressive effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 6
- 229960004801 imipramine Drugs 0.000 description 6
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 5
- 208000004130 Blepharoptosis Diseases 0.000 description 4
- 206010015995 Eyelid ptosis Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 201000003004 ptosis Diseases 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000000891 anti-reserpine Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical group O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a medicine for treating depression. The medicine is mainly prepared from hypericum perforatum and manyprickle acanthopanax root according to certain weight percentage, and has obvious curative effect on depression.
Description
[technical field]
The present invention relates to a kind of medicine for the treatment of depression and preparation method thereof, belong to the field of Chinese medicines.
[background technology]
Depression is the commonly encountered diseases of modern society, belongs to the emotion psychosis, is principal character with depressed, worried sorrow, appetite decline, insomnia, tired etc.In modern society, this disease has had a strong impact on people's work, quality of life.The WHO investigation and analysis, the prevalence of depression is about 3% in the whole world population.Along with the aggravation of social competition, this type of patient's quantity will be the trend that rises year by year.
At present, the medicine of clinical treatment depression is many based on chemical drugs, as selectivity 5-hydroxy tryptamine (5-HT) reuptake inhibitor class medicine, tricyclic antidepressant, Fourth Ring class antidepressants both at home and abroad.These Drug therapys have multiple higher side effect and more contraindication, patient can not be tolerated and be difficult to reach promising result.Therefore, people begin target diversion Chinese medicine antidepressant, disclose a kind of Chinese medicine medicine for the treatment of depression as Chinese patent application CN1381242A, and the composition of this medicine is Herba Hyperici perforati and Radix Et Caulis Acanthopanacis Senticosi.
[summary of the invention]
The objective of the invention is to disclose a kind of Chinese medicine medicine for the treatment of depression.The invention also discloses the preparation method of the medicine of this treatment depression.
Medicine of the present invention is made by following components in weight percentage:
Herba Hyperici Monogyni 51-65% Radix Et Caulis Acanthopanacis Senticosi 35-49%
The formula optimization weight percentage ranges of preparation medicine of the present invention is:
Herba Hyperici Monogyni 51-61% Radix Et Caulis Acanthopanacis Senticosi 40-49%
The optimum weight percentage ratio of medicine of the present invention is:
Herba Hyperici Monogyni 54.55% Radix Et Caulis Acanthopanacis Senticosi 45.45%
The said Herba Hyperici Monogyni of the present invention should meet in the existing national drug standards every regulation relevant under the Herba Hyperici Monogyni item; Radix Et Caulis Acanthopanacis Senticosi should meet relevant every regulation under the existing Chinese Pharmacopoeia Radix Et Caulis Acanthopanacis Senticosi item.
Adopt the routine techniques in present medical industry field, the component of above-mentioned prescription can be prepared into the pharmaceutical dosage form that the various patients of being suitable for use.
Because of capsule can improve stability of drug, production technology is simple among the present invention, is convenient to mechanization production, is advantages such as clinical common formulations, so select capsule.
The preparation method of said components being made medicine of the present invention is:
Herba Hyperici Monogyni adds 70% alcohol reflux 2 times, adds 8-12 for the first time and doubly measures ethanol, adds 6-10 for the second time and doubly measures ethanol, each reflux, extract, 0.5-1.5 hour, merge extractive liquid, filtered, decompression recycling ethanol is concentrated into the extractum of relative density about 1.10, and spray drying gets dry extract; The Radix Et Caulis Acanthopanacis Senticosi pulverizing medicinal materials becomes fragment, adds 6-10 times of water gaging, decocts 3 times, and each 1.5-3 hour, collecting decoction filtered, and filtrate is concentrated into the extractum of relative density about 1.18, and spray drying gets dry extract.Get above-mentioned two kinds of extracts, add an amount of pregelatinized starch, Pulvis Talci, magnesium stearate mix homogeneously, incapsulate, promptly.
Medicine of the present invention has following advantage:
1, with respect to similar antidepressant chemicals, it is low to have a side effect, the characteristics that contraindication is few.
2, the present invention is a capsule, taking convenience.
3, find that through test medicine of the present invention is compared with Chinese patent application CN1381242A has following advantage: a) the onset dosage of medicine of the present invention obviously reduces; B) medicine of the present invention presents obvious dose dependent, and antidepressant effect is more definite; C) medicine day clothes number of times minimizing of the present invention only need be taken twice on the 1st.
Although the preferred capsule of pharmaceutical dosage form of the present invention,, as long as adopted the composition of raw materials of medicine of the present invention, but make the pharmaceutical formulation that any other patients uses, all within protection scope of the present invention.
Medicine clearing away heat-fire of the present invention, dissipating depression of QI is calmed the nerves, kidney and spleen invigorating.Be applicable to that depression belongs to the stagnated QI transforming into fire deficiency of spleen and stomach card person that holds concurrently.Disease is seen spirit depressing, suspicious kind worry, and irritable emotion, irritated irritability, rib uncomfortable in chest expands, dizzy or headache, conjunctival congestion or tinnitus, bitter taste and dryness in the mouth, palpitation and insomnia, or accompany forgetful, anorexia, tired slow-witted weak, soreness of the waist and knees, red tongue, yellow fur, wiry and frequent pulse.
[specific embodiment]
Below further set forth the beneficial effect and the creativeness of medicine of the present invention by testing example, these are tested the pharmacodynamics that examples have comprised medicine of the present invention and Chinese patent application CN1381242A medicine (to call the A medicine in the following text) and contrast.
1, the mandatory swimming test of rat
(1) observes animal continuous oral various dose medicine of the present invention with the mandatory swimming test of classical depressed animal model rat, to reducing the action effect of the mandatory non-swimming time of rat (second), estimate medicine of the present invention and take the different of number of times in onset dosage, antidepressant effect and day with the A medicine.Result of the test: the oral medicine 15.6-250mg/kg dosage of the present invention of rat, 2 administrations in 24,1 hours before test, compare with the solvent control group, 31.3mg/kg, 62.5mg/kg, 125mg/kg group significantly reduces the dead time, be dose relationship, have significance,statistical (P＜0.001, P＜0.01 and P＜0.05), the positive control drug imipramine also shows same purpose (table 1).
2 times/day influences of the oral medicine of the present invention of table 1. rat to the forced swimming dead time
| Medicine | Dosage (mg/kg) | Route of administration | Number of animals (n) | Dead time (second) M ± SD |
| Solvent control group imipramine medicine of the present invention | 10.0 15.6 31.3 62.5 125.0 250.0 | Po Ip Po Po Po Po Po | 15 15 15 15 15 15 15 | 108.8±30.5 37.4±32.1*** 90.5.0±42.3 73.2±45.8* 65.7±35.4** 58.9±36.2*** 79.5±53.1 |
Compare with the solvent control group: * P＜0.05; * P; * * P＜0.001
(2) use with quadrat method A medicine and the results are shown in Table 2 with the mandatory swimming test of classical depressed animal model rat
3 times/day influences of the oral A medicine of table 2. rat to the forced swimming dead time
| Medicine | Dosage (mg/kg) | Route of administration | Number of animals (n) | Dead time (second) M ± SD |
| Solvent control group imipramine A medicine | 10.0 15.6 31.3 62.5 125.0 250.0 500.0 | Po Ip Po Po Po Po Po Po | 27 13 10 16 16 16 16 13 | 101.8±35.7 36.4±32.7** 124.0±59.3 89.2±56.3 70.3±41.2** 73.3±48.4* 89.5±53.1 93.9±47.4 |
Compare with the solvent control group: * P＜0.05; * P＜0.01;
Result of the test by table 1 and table 2 can show: oral 2 times of (1) medicine of the present invention every day, under 31.3mg/kg dosage, just significantly reduce the mandatory non-swimming time of rat, and the A medicine needs oral 3 times every day, and under 62.5mg/kg dosage, could significantly reduce the mandatory non-swimming time of rat, therefore the onset dosage of medicine of the present invention is obviously low than A medicine, and a day clothes number of times also lacks than the A medicine.(2) oral 2 times of medicine of the present invention every day, the action effect under 31.3mg/kg, 62.5mg/kg, 125mg/kg dosage is obvious dose dependent; And the A medicine is better than 125mg/kg at the action effect of 62.5mg/kg, and is simultaneously invalid under 250mg/kg, 500mg/kg dosage, so Drug therapy curative effect of depression of the present invention is more definite.
2, mouse tail suspension test
(1) with the classical depressed animal model of mouse tail suspension, observe mice continuous oral various dose medicine of the present invention, to reducing the action effect of mouse tail suspension dead time (second), estimate medicine of the present invention and take the different of number of times in onset dosage, antidepressant effect and day with the A medicine.Result of the test: the oral medicine of the present invention of mice is under 31.3-250mg/kg dosage, 1 time/day, successive administration 5 times, 62.5mg/kg, 125mg/kg, 250mg/kg have significance to the mouse tail suspension dead time and reduce, and be dose dependent relation, have statistical significance (P＜0.01 and P＜0.05) (table 3), the positive control drug imipramine also shows same purpose.
Continuous 5 the influences of the oral medicine of the present invention of table 3. mice (1 time/day) to the outstanding tail dead time
| Medicine | Dosage (mg/kg) | Route of administration | Number of animals (n) | The outstanding tail dead time (second) (M ± SD) |
| Solvent control imipramine medicine of the present invention | 10.0 31.3 62.5 125.0 250.0 | Po Ip Po Po Po Po | 15 15 15 15 15 15 | 107.7±33.3 48.5±37.2*** 97.2±35.2 85.6±24.2* 80.4±32.6* 73.5±36.0** |
Compare with matched group: * P＜0.01; * P＜0.01; * 8 P＜0.001
(2) use with quadrat method A medicine result of the test on the classical depressed animal model of mouse tail suspension and see Table 4
Continuous seven the influences of the oral A medicine of table 4. mice (2 times/day) to the outstanding tail dead time
| Medicine | Dosage (mg/kg) | Route of administration | Number of animals (n) | The outstanding tail dead time (second) (M ± SD) |
| Solvent control imipramine Desipramine A medicine | 10.0 10.0 62.5 125.0 250.0 500.0 | Po Ip Ip Po Po Po Po | 28 17 16 16 16 16 16 | 111.7±34.3 52.5±33.2** 69.8±33.8** 101.3±32.2 86.6±24.2** 101.4±46.2 116.7±38.0 |
Compare with matched group: * * P＜0.01;
Result of the test by table 3 and table 4 can show: oral 1 time of (1) medicine of the present invention every day, successive administration 5 times just significantly reduces the mouse tail suspension dead time under 62.5mg/kg dosage; And the A medicine needs need every day oral 2 times, and successive administration 7 times could reduce the mouse tail suspension dead time under 125mg/kg dosage, so the onset dosage of medicine of the present invention is obviously low than A medicine, and a day clothes number of times also lacks than the A medicine.(2) oral 1 time of medicine of the present invention every day, continuous 5 times, the action effect under 62.5mg/kg, 125mg/kg, 250mg/kg dosage is obvious dose dependent; And the A medicine only just has action effect under 125mg/kg dosage, and is invalid under 250mg/kg, 500mg/kg dosage, so Drug therapy curative effect of depression of the present invention is more definite.
3, anti-reserpine eye blepharoptosis depression model test
In order further to prove the curative effect of medicine of the present invention to treatment depression aspect, also carried out anti-reserpine eye blepharoptosis depression model test, by mice continuous oral various dose medicine of the present invention, observe and respectively to organize in the mice eye face and close animal number over half at least, estimate the antidepressant curative effect of medicine of the present invention.Result of the test sees Table 5.
1 time/day administration of table 5 medicine of the present invention causes the influence of blepharoptosis to the mice reserpine
| Group | Dosage * number of times (mg/kg * c) | Mus number (only) | Eyelid is closed number of animals over half (only) at least |
| Normal group depression model group clomipramine hydrochloride sheet group hydrochloric venlafaxine new capsule Kaiyuamshen capsule group Kaiyuamshen capsule group Kaiyuamshen capsule group | Isometric(al) distilled water isometric(al) distilled water 10 * 5 30 * 5 62.5 * 5 125 * 5 250 * 5 | 10 10 10 10 10 10 10 | 0 10 5*** 6*** 5*** 6*** 7** |
Annotate: each administration group and depression model group be * * P＜0.01 * * * P＜0.001 relatively
Table 5 shows, 62.5mg/kg, 125mg/kg, 250mg/kg medicine of the present invention oral 1 time on the one, behind the successive administration 5 times reserpine is caused mice eye blepharoptosis and have the significance antagonism, and under three dosage, be dose-dependence, prove that medicine of the present invention has antidepressant effect.
Come further to set forth medicine of the present invention by the following examples
Embodiment 1
Herba Hyperici Monogyni 1800 gram Radix Et Caulis Acanthopanacis Senticosis 1500 grams
Preparation method is as follows:
Take by weighing two herbal medicines of above-mentioned formula ratio, wherein Herba Hyperici Monogyni adds 70% alcohol reflux 2 times, add for the first time 10 times of amount ethanol, add for the second time 8 times of amount ethanol, each reflux, extract, 1 hour, merge extractive liquid,, filter, decompression recycling ethanol is concentrated into the extractum of relative density 1.10, and spray drying gets dry extract; The Radix Et Caulis Acanthopanacis Senticosi pulverizing medicinal materials becomes fragment, adds 8 times of water gagings, decocts 3 times, and each 2 hours, collecting decoction filtered, and filtrate is concentrated into the extractum of relative density 1.18, and spray drying gets dry extract.Get above-mentioned two kinds of extracts, add an amount of pregelatinized starch, Pulvis Talci, magnesium stearate mix homogeneously, 1000 capsules of packing into, promptly.
Embodiment 2
Herba Hyperici Monogyni 52% Radix Et Caulis Acanthopanacis Senticosi 48%
Preparation method is with embodiment 1
Embodiment 3
Herba Hyperici Monogyni 62% Radix Et Caulis Acanthopanacis Senticosi 38%
Preparation method is with embodiment 1
Claims (6)
1, a kind of medicine for the treatment of depression is characterized in that it mainly is to be made by following raw material medicines in percentage by weight:
Herba Hyperici Monogyni 65%, Radix Et Caulis Acanthopanacis Senticosi 35%.
2, a kind of medicine for the treatment of depression is characterized in that it mainly is to be made by following raw material medicines in percentage by weight:
Herba Hyperici Monogyni 62%, Radix Et Caulis Acanthopanacis Senticosi 38%.
3, a kind of medicine for the treatment of depression is characterized in that it mainly is to be made by following raw material medicines in percentage by weight:
Herba Hyperici Monogyni 54.55%, Radix Et Caulis Acanthopanacis Senticosi 45.45%.
4, according to the medicine of claim 1,2 or 3 described treatment depressions, the dosage form that it is characterized in that this medicine is a capsule.
5, the preparation method of the medicine of treatment depression according to claim 4, it is characterized in that: Herba Hyperici Monogyni adds 70% alcohol reflux 2 times, for the first time add 8-12 and doubly measure ethanol, for the second time add 6-10 and doubly measure ethanol, each reflux, extract, 0.5-1.5 hour, merge extractive liquid,, filter, decompression recycling ethanol is concentrated into the extractum of relative density 1.10, and spray drying gets dry extract; The Radix Et Caulis Acanthopanacis Senticosi pulverizing medicinal materials becomes fragment, adds 6-10 times of water gaging, decocts 3 times, and each 1.5-3 hour, collecting decoction filtered, and filtrate is concentrated into the extractum of relative density 1.18, and spray drying gets dry extract.Get above-mentioned two kinds of extracts, add an amount of pregelatinized starch, Pulvis Talci, magnesium stearate mix homogeneously, incapsulate, promptly.
6, according to the method for claim 5, wherein to add amount of alcohol for the first time be 10 times to Herba Hyperici Monogyni, and adding amount of alcohol for the second time is 8 times, decocts 1 hour at every turn; Radix Et Caulis Acanthopanacis Senticosi adds 8 times of water gagings, decocts 2 hours at every turn.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117484 CN1273150C (en) | 2003-03-19 | 2003-03-19 | Medicine for treating depression and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117484 CN1273150C (en) | 2003-03-19 | 2003-03-19 | Medicine for treating depression and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1531954A CN1531954A (en) | 2004-09-29 |
| CN1273150C true CN1273150C (en) | 2006-09-06 |
Family
ID=34284737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03117484 Expired - Lifetime CN1273150C (en) | 2003-03-19 | 2003-03-19 | Medicine for treating depression and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1273150C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055812B (en) * | 2014-03-13 | 2017-07-21 | 江苏康缘药业股份有限公司 | A kind of composition and preparation method and purposes with antidepressant effect |
| CN108283674A (en) * | 2018-03-06 | 2018-07-17 | 深圳市蓝能健康科技有限公司 | Medicine for treating and regulating depression and product for preparing medicine |
| CN112741887B (en) * | 2019-10-30 | 2022-02-18 | 唐启盛 | Traditional Chinese medicine composition for treating depression |
-
2003
- 2003-03-19 CN CN 03117484 patent/CN1273150C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1531954A (en) | 2004-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102462825B (en) | Compound traditional Chinese medicine for treating depression | |
| CN1273150C (en) | Medicine for treating depression and its preparing method | |
| CN1799564A (en) | Application of valeriana wallichii and its extract in preparation of medicine for treating anxiety neurosis | |
| CN105031553B (en) | Pharmaceutical composition for treating dog dermatomycosis and preparation method and application thereof | |
| CN1724014A (en) | Extractive of total saponin of clematis root, prepn. method and pharmaceutical use thereof | |
| CN1861116A (en) | Traditional Chinese medicine prepn. for treating anxiety disorders and depressive disorders | |
| CN1282468C (en) | Chinese medicine soft capsule Naodesheng and its preparing method | |
| CN102018870A (en) | Traditional Chinese medicine composition for preventing and treating liver diseases and preparation method thereof | |
| CN1246000C (en) | Guangsheng hemp extract, its preparing method and use | |
| CN1183946C (en) | Medicines for treating depression and preparation thereof | |
| CN1966051A (en) | Antivirus medicament | |
| CN1383867A (en) | Medicine for treating depression and its prepn | |
| CN1943691A (en) | A Chinese traditional medicinal composition for treatment of osteoporosis and its preparation method | |
| CN1853711A (en) | Xinmaikangzhong Chinese medicinal composition and preparation thereof | |
| CN1310650C (en) | Application of saponins in the preparing process of coxsackie virus resisting medicine | |
| CN1471914A (en) | Medicine, application and preparing method for preventnig SARS pneumonia by SARS virus | |
| CN1203891C (en) | Medicine for treating coronary heart disease and its preparation method | |
| CN1291103A (en) | Herbal composition for the prophylaxis and treatment of AIDS | |
| CN116115679B (en) | Application of radix Tripterygii Wilfordii extract in preparing medicine for treating sepsis related encephalopathy | |
| CN1268343C (en) | Compositions of asiatic centella and Hypericum perforatum extracts and its antidepressant action | |
| CN1282480C (en) | Head ache capsule preparation | |
| CN1943732A (en) | A medicinal composition for treatment of psoriasis | |
| CN101040920A (en) | Drug for curing nephrosis and its preparing method | |
| CN1857411A (en) | Chinese medicine capsule for treating AIDS and its preparing method | |
| CN116617319A (en) | Traditional Chinese medicine composition for improving clinical symptoms of HIV infected person, preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHENGDU KANGHONG MEDICINE GROUP CO.LTD. Free format text: FORMER OWNER: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO., LTD. Effective date: 20080912 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080912 Address after: No 36, Shu West Road, Chengdu, Sichuan, Jinniu District Patentee after: CHENGDU KANGHONG PHARMACEUTICAL Co.,Ltd. Address before: No. 36 Shu West Road, Sichuan, Jinniu District Patentee before: Chengdu Kanghong technology industry (Group) Co.,Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20040929 Assignee: Sichuan Jishengtang Pharmaceutical Co.,Ltd. Assignor: CHENGDU KANGHONG PHARMACEUTICAL Co.,Ltd. Contract record no.: 2017510000031 Denomination of invention: Medicine for treating depression and its preparing method Granted publication date: 20060906 License type: Common License Record date: 20171018 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201021 Address after: Pengzhou City, Chengdu City, Sichuan province 611930 days Peng Zhen Hua Long Road No. 89 Patentee after: Sichuan Jishengtang Pharmaceutical Co.,Ltd. Address before: 610036 Jinniu District, Sichuan, Sichuan West Road, No. 36, No. Patentee before: CHENGDU KANGHONG PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060906 |
|
| CX01 | Expiry of patent term |